Reuters logo
BRIEF-Ligand enters commercial license, supply agreements for captisol-enabled Trametinib
December 22, 2016 / 2:23 PM / a year ago

BRIEF-Ligand enters commercial license, supply agreements for captisol-enabled Trametinib

Dec 22 (Reuters) - Ligand Pharmaceuticals Inc :

* Ligand Pharmaceuticals Inc - Novartis will be responsible for all costs related to program

* Ligand Pharmaceuticals - ligand will be eligible to receive a license fee, royalties on future net sales, and revenue from Captisol material sales

* Ligand enters commercial license and supply agreements for Captisol-enabled Trametinib Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below